As treatment for schizophrenia changes, LAIs are becoming increasingly important as maintenance therapy. Teva's pursuit of an ...
Dual art therapy, combining music and painting, significantly improved symptoms, cognitive function, and quality of life in ...
Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a ...
Neurocrine Biosciences ($NBIX) announced an update on their ongoing clinical study. Neurocrine Biosciences has initiated a Phase 3 study titled ‘A ...
Cobenfy’s efficacy at treating the symptoms of patients with psychosis may vary between subgroups, according to a post-hoc ...
In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...
Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares began Tuesday sharply higher. The company today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug ...
CINCINNATI, Ohio. (Ivanhoe Newswire) --- Schizophrenia - the statistics are terrifying; more than 3.7 million people are living with it right now in the United States. If left untreated it can be ...
Schizophrenia is a mental health disorder that causes changes to the way a person thinks, acts, and behaves. People with schizophrenia may have hallucinations, delusions, disorganized behavior, and ...
Morning Overview on MSN
'Brainquake' find could rewrite what we know about schizophrenia
Schizophrenia has long been framed as a disorder of broken thoughts and fractured perception, but a new line of research ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback